Vimovo

vimovo

Horizon Pharma plc has rights to commercialize VIMOVO® (naproxen/esomeprazole magnesium) within the United States. AstraZeneca has commercialization rights to VIMOVO outside the United States. Aralez is entitled to receive a 10% royalty on net sales of products sold in the United States, with guaranteed annual minimum royalty payments of $7.5 million provided that the patents owned by Aralez that cover VIMOVO are in effect and no generic forms of VIMOVO are on the market.

VIMOVO is approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID associated gastric ulcers.

Important Safety Information

  • Like all medications that contain nonsteroidal anti-inflammatory drugs (NSAIDs), VIMOVO may increase the  chance of a heart attack or stroke that can lead to death. This chance increases with longer use of NSAID medicines in people who have heart disease.
  • NSAID-containing medications, such as VIMOVO, should never be used before or after a type of heart surgery called coronary artery bypass graft (CABG).
  • As with all medications that contain NSAIDs, VIMOVO may increase the chance of stomach and intestinal problems, such as bleeding or an ulcer, which can occur without warning and may cause death.

Elderly patients are at greater risk for serious gastrointestinal events.

This product information is intended only for residents of the United States.